Clinical Trial

A Real-world Study of Patients With Hidradenitis Suppurativa and High Cardiovascular Risk or Established Coronary Plaque Treated With Secukinumab

Study acronym: HOPE
Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
The aim of this study is to assess the real-world effects of secukinumab in adult participants with moderate-to-severe Hidradenitis Suppurativa (HS), particularly focusing on its potential impact on coronary atherosclerotic plaque progression or stability. Participants will be enrolled at a single dermatology and cardiology center in Italy and will receive secukinumab as part of their routine clinical care
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2026-03-03; most recent amendment 2026-07-21.
Trial Details
NCT Number NCT07454889
Lead Sponsor Novartis Pharmaceuticals
Conditions Hidradenitis Suppurativa
Enrollment 34 participants
Start Date 2026-07-31
Primary Completion 2027-03-31 (estimated)
Study Completion 2027-03-31 (estimated)
Updated on ClinicalTrials.gov 2026-07-22